Top

BMC Cancer

Published in:

Open Access 01-12-2012 | Research article

The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients

Authors: Catharina Medrek, Fredrik Pontén, Karin Jirström, Karin Leandersson

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163⁺ and CD68⁺ myeloid cells in human breast cancer.

Methods

The extent of infiltrating CD163⁺ or CD68⁺ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ² tests were used to examine the correlations between CD163⁺ or CD68⁺ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163⁺ and CD68⁺ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival.

Results

We found that infiltration of CD163⁺ and CD68⁺ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163⁺ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163⁺ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68⁺ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival.

Conclusion

These findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.

Available only for authorised users

Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed

Sica A, Schioppa T, Mantovani A, Allavena P: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006, 42 (6): 717-727. 10.1016/j.ejca.2006.01.003.CrossRefPubMed

Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.CrossRefPubMed

Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G: Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000, 67 (1): 97-103.PubMed

Lau SK, Chu PG, Weiss LM: CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004, 122 (5): 794-801. 10.1309/QHD6YFN81KQXUUH6.CrossRefPubMed

Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y: Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005, 29 (5): 617-624. 10.1097/01.pas.0000157940.80538.ec.CrossRefPubMed

Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, Tak PP, Baeten DL: Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012, 375 (1–2): 196-206.CrossRefPubMed

Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196 (3): 254-265. 10.1002/path.1027.CrossRefPubMed

Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56 (20): 4625-4629.PubMed

10.

Lee AH, Happerfield LC, Bobrow LG, Millis RR: Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol. 1997, 50 (8): 669-673. 10.1136/jcp.50.8.669.CrossRefPubMedPubMedCentral

11.

Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24 (14): 2137-2150. 10.1200/JCO.2005.05.2308.CrossRefPubMed

12.

Holness CL, Simmons DL: Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993, 81 (6): 1607-1613.PubMed

13.

Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009, 27 (20): 3330-3337. 10.1200/JCO.2008.19.9919.CrossRefPubMed

14.

Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C: Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007, 5: 62-10.1186/1479-5876-5-62.CrossRefPubMedPubMedCentral

15.

Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, et al: Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest. 2011, 121 (2): 784-799. 10.1172/JCI43757.CrossRefPubMedPubMedCentral

16.

Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S, Jirstrom K, Belting M: Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol. 2011, 39 (6): 1421-1428.PubMed

17.

Gronberg M, Fjallskog ML, Jirstrom K, Janson ET: Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. ActaOncol. 2012, 51 (3): 386-393.

18.

Rexhepaj E, Jirstrom K, O’Connor DP, O’Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM: Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer. 2010, 10: 639-10.1186/1471-2407-10-639.CrossRefPubMedPubMedCentral

19.

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009, 7 (1–2): 4-13.CrossRefPubMedPubMedCentral

20.

Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, Chebil G, Jonsson PE, Ferno M, Landberg G: Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol. 2005, 58 (11): 1135-1142. 10.1136/jcp.2005.027185.CrossRefPubMedPubMedCentral

21.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005, 24 (29): 4660-4671. 10.1038/sj.onc.1208561.CrossRefPubMed

22.

Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004, 5 (6): 607-616. 10.1016/j.ccr.2004.05.015.CrossRefPubMed

23.

Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R: NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res. 2005, 33 (Database issue): D562-D566.CrossRefPubMed

24.

Maniecki MB, Moller HJ, Moestrup SK, Moller BK: CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology. 2006, 211 (6–8): 407-417.CrossRefPubMed

25.

Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 11 (10): 889-896. 10.1038/ni.1937.CrossRefPubMed

26.

Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G, Inoue M: orrelation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 24 (5C): 3335-3342.PubMed

27.

Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N: The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003, 23 (6D): 5015-5022.PubMed

28.

Steele RJ, Eremin O, Brown M, Hawkins RA: Oestrogen receptor concentration and macrophage infiltration in human breast cancer. Eur J Surg Oncol. 1986, 12 (3): 273-276.PubMed

29.

Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, et al: Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011, 128 (3): 703-711. 10.1007/s10549-010-1154-y.CrossRefPubMed

30.

Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA: The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol. 2012, 38 (4): 307-313. 10.1016/j.ejso.2012.01.002.CrossRefPubMed

31.

Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008, 8 (8): 618-631. 10.1038/nrc2444.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/306/prepub

Title: The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
Authors: Catharina Medrek
Fredrik Pontén
Karin Jirström
Karin Leandersson
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-306

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Biomarkers for antitumor activity of bevacizumab in gastric cancer models

Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia

miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma

LINE-1 methylation shows little intra-patient heterogeneity in primary and synchronous metastatic colorectal cancer

Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system

Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer